Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Earnings for Biogen Inc. (BIIB)
Earnings in 2023 (TTM): $1.3 B
According to Biogen Inc.'s latest financial reports the company's current earnings (TTM) are $1.3 B. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Biogen Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $1.3 B | $1.16 B |
| 2022 | $3.59 B | $3.05 B |
| 2021 | $1.75 B | $1.56 B |
| 2020 | $5.05 B | $4 B |
| 2019 | $7.13 B | $5.89 B |
| 2018 | $5.9 B | $4.43 B |
| 2017 | $5.13 B | $2.54 B |
| 2016 | $4.93 B | $3.7 B |
| 2015 | $4.77 B | $3.55 B |
| 2014 | $3.95 B | $2.93 B |
| 2013 | $2.48 B | $1.86 B |
| 2012 | $1.86 B | $1.38 B |
| 2011 | $1.71 B | $1.23 B |
| 2010 | $1.23 B | $1.01 B |
| 2009 | $1.33 B | $970.13 M |
| 2008 | $1.15 B | $783.17 M |
| 2007 | $910.6 M | $638.17 M |
| 2006 | $492.16 M | $217.51 M |
| 2005 | $256.2 M | $160.71 M |
| 2004 | $64.09 M | $25.09 M |
| 2003 | $-880,624,000 | $-875,097,000 |
| 2002 | $276.6 M | $199.15 M |
| 2001 | $389.5 M | $272.68 M |
| 2000 | $487.11 M | $333.58 M |
| 1999 | $329.02 M | $220.45 M |
| 1998 | $210.19 M | $138.7 M |
| 1997 | $148.97 M | $89.17 M |
| 1996 | $40.83 M | $40.53 M |
| 1995 | $7.45 M | $5.66 M |
| 1994 | $-1,907,000 | $-4,897,000 |
| 1993 | $34.6 M | $32.4 M |
| 1992 | $39.9 M | $38.3 M |
| 1991 | $7.5 M | $7.2 M |
| 1990 | $8 M | $7.7 M |
| 1989 | $3.4 M | $3.2 M |
| 1988 | $-900,000 | $-1,200,000 |
| 1987 | $-22,400,000 | $-22,600,000 |
| 1986 | $-27,800,000 | $-28,200,000 |
| 1985 | $-18,700,000 | $-19,100,000 |